{
  "abstract": "Daratumumab is a monoclonal antibody targeting CD38 and is widely used in the treatment of multiple myeloma. While generally well tolerated, pulmonary toxicity is a rare and under-recognised adverse effect. We present the case of an elderly woman with multiple myeloma on maintenance daratumumab therapy who developed subacute hypoxic respiratory failure. Imaging revealed new-onset diffuse bilateral ground-glass opacities. Bronchoscopy with lavage was non-diagnostic. Extensive infectious and rheumatologic workup was unrevealing. The patient improved significantly with corticosteroids and discontinuation of daratumumab, supporting a diagnosis of drug-induced pneumonitis. This case highlights the importance of considering monoclonal antibody-induced lung injury in the differential diagnosis of respiratory symptoms in patients receiving long-term CD38-directed therapy.",
  "authors": [
    {
      "affiliations": [
        "Family Medicine, Onvida Health, Yuma, Arizona, USA"
      ],
      "name": "Navroop Momi"
    },
    {
      "affiliations": [
        "Family Medicine, Onvida Health, Yuma, Arizona, USA"
      ],
      "name": "Vaiishnavi Ramesh"
    },
    {
      "affiliations": [
        "Critical Care, Yuma Regional Medical Center, Yuma, Arizona, USA"
      ],
      "name": "Aneesh Kumar Vasudevan"
    },
    {
      "affiliations": [
        "Pulmonary and Critical Care, Onvida Health, Yuma, Arizona, USA"
      ],
      "name": "Kulothungan Gunasekaran"
    }
  ],
  "title": "Acute interstitial pneumonitis associated with daratumumab treatment",
  "uid": "0f0548bc-003a-552a-b722-f01bb5d5d8aa"
}